Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age - Wikidata - awgldk - TriplyDB

Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age

Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age

http://www.wikidata.org/entity/Q33838116

about

Interpreting outcome data in hematopoietic cell transplantation for leukemia: tackling common biases.Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic.Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis.Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation?Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.Allogeneic hematopoietic cell transplantation in septuagenarians Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research Hematopoietic Stem Cell Transplant in Elderly Patients: Experience from a Tertiary Care Centre in Northern India.Allogeneic hematopoietic cell transplantation in patients ⩾70 years: which patients may benefit?Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia.Acute myeloid leukaemia in the elderly: a review.Emerging immunotherapies in older adults with acute myeloid leukemia.To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century.Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients.Patterns of Care and Survival for Elderly Acute Myeloid Leukemia-Challenges and Opportunities.Healthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic Hematopoietic Cell Transplantation.Recommended screening and preventive evaluation practices of adult candidates for hematopoietic stem cell transplantation.Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia.CD25 as an adverse prognostic factor in elderly patients with acute myeloid leukemia.Influence of age on outcome after allogeneic hematopoietic cell transplantation: a single center study in patients aged ⩾60.Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen for elderly patients (60 years and older) with hematologic malignancies using unrelated donors: a retrospective study from the French society for stem ce Are reduced-intensity transplants safe in older patients with hematologic malignancies?Frailty: the missing piece of the pre- hematopoietic cell transplantation assessment?Quality of life and outcomes in patients⩾60 years of age after allogeneic hematopoietic cell transplantation.Age does not adversely influence outcomes among patients older than 60 years who undergo allogeneic hematopoietic stem cell transplant for AML and myelodysplastic syndrome.Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: a British Society of Blood and Marrow Transplantation study.Single center retrospective analysis of BU-based conditioning regimens in allogeneic transplantation.

P2860

Q30884173-9FDB50AB-2A55-48E1-81AE-1C300DD59CED Q33566684-427D7BE9-B991-485B-BB31-381A63D305AD Q33850163-98633D95-9949-4986-9143-7346082B674C Q33859061-D9830632-31B6-46FF-907D-D399A93F6D5B Q34013826-22313485-8A0A-4CB2-A5C2-CB684060E614 Q34667853-4A434ED7-B48E-4AA1-A90E-ACFBDF454364 Q35766718-F91C3ACD-CD67-48FD-86C8-78332B4FECE6 Q36579065-F79A54FD-B8C6-4365-BF21-7BE28C6F4452 Q37048479-C67304A5-1D24-4132-A5BC-C44AD9CB53F4 Q37270993-4AECB522-D96B-49C6-A0EF-193B5CD71E5A Q37301516-A929276A-2EFB-40AD-8E2C-48C43B89BFC0 Q37810123-A88378A6-7ACE-4FF3-ACDA-141932215507 Q37840260-3ADDB8DC-ADD2-441F-AC47-856CA8891914 Q38075407-D3420FB7-178C-4853-9D09-FB77E0C91528 Q38104287-C0824938-839D-47C6-99D6-C707896A20BB Q38106983-90593F73-691B-4C8A-8639-F1DB3EE13391 Q38161965-9D296CE3-43B5-40FD-9239-75D9FB586E36 Q38676390-5F83E6AD-1723-4EB4-9BAF-4AA37A478480 Q38926882-BE575079-EC3E-4ECB-80AB-675656FFE9CF Q38937601-5C6F3D8C-4C74-49C5-9872-A6AA757ADA88 Q39002065-3A1EA943-B23B-4C31-8C34-80530BE7FF60 Q40216218-9732DF9C-0FEB-4684-918E-08239ECDC046 Q40376093-574AD3DD-1EFA-4012-BF44-E2587378EDE4 Q41564676-EE10C661-AD66-4CB7-BAD6-69036E52B883 Q42397451-478BF01C-4A45-49DA-9D6B-75BCADC8FF65 Q47576700-0A804142-0D30-4018-987E-623970D95555 Q47869630-F73213D1-7F1D-48EE-9865-2F1D14BDA9C6 Q48069751-4E7586D8-5511-4466-844A-069AC69EF10F Q48133412-5CA7C508-9427-4268-A235-E9D9C84BD9AF Q52838715-06B8DF56-6D9C-4CF2-8ACB-E6E3E975086F Q54051617-11687284-18C9-45EB-9BE0-5E9F826107F0

P2860

Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age

http://www.wikidata.org/entity/Q33838116

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Reduced-intensity conditioning ...... e not impaired in advanced age

@ast

Reduced-intensity conditioning ...... e not impaired in advanced age

@en

type

label

Reduced-intensity conditioning ...... e not impaired in advanced age

@ast

Reduced-intensity conditioning ...... e not impaired in advanced age

@en

prefLabel

Reduced-intensity conditioning ...... e not impaired in advanced age

@ast

Reduced-intensity conditioning ...... e not impaired in advanced age

@en

P1433

Q33838116-C28C33EF-2543-4EF4-A161-55C141B78BED

P1476

Q33838116-50B5835C-C879-4450-9E4D-4E05F055486D

P2093

Q33838116-01440C09-8B61-4765-8F6A-BF96E4607098

Q33838116-19B9DD8D-1B3C-4DD3-ABD6-F48735B28535

Q33838116-45C8BA83-CC6A-4682-B871-45882EC6120F

Q33838116-7931407F-1C83-40B2-88D2-4C996CED32C1

Q33838116-864F6525-D2CC-486C-BC25-C96CC4B0F082

Q33838116-A64BC63C-8684-427D-A14B-D93A517D096E

Q33838116-BA78839D-825E-4E24-A122-1259C6CA9767

Q33838116-BB2A8CA3-B0C2-45D0-927C-E2C654DA6E10

Q33838116-BCFC5613-5FBE-4C1A-B006-574C2068EDED

Q33838116-FF09265C-6AB2-4CF7-9EC5-9923882FBBC6

P2860

Q33838116-0375916C-B433-45F6-A441-88433E416397

Q33838116-153073B1-056B-4349-8DE8-B612F786020E

Q33838116-3BDA8B26-006F-4A7D-AF39-1DDA09D77382

Q33838116-48B5767D-E70A-469E-AD12-096A850ADC46

Q33838116-6FD79470-A027-4670-BCF2-8BF5DE183455

Q33838116-750DC22D-6278-46EB-99DA-195E6012E2FD

Q33838116-80B5EC73-EFCA-4E1A-994B-469382610AE1

Q33838116-859C617B-09A8-4CC2-963D-9C79764B0E6E

Q33838116-9123599A-12CF-41D8-B32C-2DA8B4036B88

Q33838116-938E2149-991C-42F4-AFAC-5600F1F5BC30

P304

Q33838116-C184BF28-EAD3-4269-8EC6-5B7730A78FF4

P31

Q33838116-0FCD94D9-0BAD-4A4D-8D31-31CCF5012277

P356

Q33838116-584B973C-04A7-4EDD-B281-740EC272CBFB

P433

Q33838116-716F6C12-0B4D-4C33-BA15-951024F5A232

P478

Q33838116-D3E5D8A9-9198-4C95-B1E1-7D884EF5B37F

P577

Q33838116-120E5D84-22E8-4DB0-ABCA-BA72538B8F69

P5875

Q33838116-0773E8D7-9814-4937-AA3A-A3BCBFC55A0E

P698

Q33838116-02C07423-5A44-4607-BC7D-E014FC4694C0

P932

Q33838116-D3A66676-3935-433F-8204-428EF7F1AF8A

P356

J.BBMT.2009.12.537

P1433

Biology of Blood and Marrow Transplantation

P1476

Reduced-intensity conditioning ...... e not impaired in advanced age

@en

P2093

Corey Cutler

http://www.w3.org/2001/XMLSchema#string

Edwin P Alyea

http://www.w3.org/2001/XMLSchema#string

Haesook T Kim

http://www.w3.org/2001/XMLSchema#string

Jerome Ritz

http://www.w3.org/2001/XMLSchema#string

John Koreth

http://www.w3.org/2001/XMLSchema#string

Joseph H Antin

http://www.w3.org/2001/XMLSchema#string

Julie Aldridge

http://www.w3.org/2001/XMLSchema#string

Philippe Armand

http://www.w3.org/2001/XMLSchema#string

Robert J Soiffer

http://www.w3.org/2001/XMLSchema#string

Vincent T Ho

http://www.w3.org/2001/XMLSchema#string

P2860

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

International scoring system for evaluating prognosis in myelodysplastic syndromes

Cancer statistics, 2009

Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.

Age and acute myeloid leukemia.

Optimal management of adults with ALL.

Hodgkin lymphoma in older patients: an uncommon disease in need of study.

Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation

P304

792-800

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBMT.2009.12.537

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41027707

http://www.w3.org/2001/XMLSchema#string

P698

20074656

http://www.w3.org/2001/XMLSchema#string

P932

2866750

http://www.w3.org/2001/XMLSchema#string